FindTrial
Sign In

Evaluating the Role of Intratracheal Dexmedetomidine in Post-Extubation Cough Suppression: A one year Hospital-Based Study

Evaluation of the effect of low dose intratracheal Dexmedetomidine for attenuation of postextubation cough- A. One year hospital based Randomised Clinical Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/086166
Enrollment
80
Registered
2025-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Intratracheal dexmedetomidine: The patient would be administered dexmedetomidine 0.3 mcg/kg intra tracheal using Tuberculin syringe (diluted to 2 ml with NS to ensure adequate entry int

Sponsors

Sumeet Kaur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA Grade I and II Patients between age group of 18-60 years Patients undergoing surgery under general anaesthesia with Endotracheal tube.

Exclusion criteria

Exclusion criteria: Patient allergic to study drug Patients undergoing general anaesthesia with supraglottic airway devices Patient with pre operative sore throat or upper respiratory tract infections

Design outcomes

Primary

MeasureTime frame
To study the effect of low dose intra tracheal dexmedetomidine on incidence and severity of postextubation cough Timepoint: Immediately after extubation Every hourly till the first 6 hours Every 4 hours till 24 hours—

Secondary

MeasureTime frame
To determine the side effects of study drug Timepoint: After the introduction of the drug till the end of the procedure & continued followup for 24 hours.—

Countries

India

Contacts

Public ContactVandana Gogate

JawaharLal Nehru Medical College

vandanagogate@gmail.com9844083030

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026